Novartis Completes Divestiture of Influenza Vaccines Business to CSL Limited for $275M

Loading...
Loading...
CSL Limited acquired influenza vaccines business of Novartis
NVS
, including influenza vaccines development pipeline Basel, Switzerland, August 3, 2015 - Novartis today announced that it has completed effective July 31, 2015 the divestiture of its influenza vaccine unit to CSL Limited. This marks the end of a series of transactions previously announced and completed,that are focusing Novartis on its three leading businesses of global scale - pharmaceuticals, generics and eye care. Since April 2014, the influenza vaccines unit results have been reported under Discontinuing Operations in the Novartis consolidated financial statements. DisclaimerClosing in certain jurisdictions is subject to statutory employee consultation. The foregoing release contains forward-looking statements that can be identified by words such as "pipeline," "are focusing," or similar terms, or by express or implied discussions regarding any potential strategic benefits, synergies or opportunities as a result of the announced transactions. You should not place undue reliance on these statements. Such forward-looking statements are based on the current
See full press release
Posted In: NewsAsset SalesM&APress Releases
We simplify the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...